Glaukos Corporation (GKOS)

Market Cap	6.94B
Revenue (ttm)	383.48M
Net Income (ttm)	-146.37M
Shares Out	55.11M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,139,635
Open	141.35
Previous Close	157.36
Day's Range	124.95 - 142.95
52-Week Range	83.90 - 163.71
Beta	1.05
Analysts	Strong Buy
Price Target	161.00 (+27.9%)
Earnings Date	Feb 20, 2025

About GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 907
• Stock Exchange: NYSE
• Ticker Symbol: GKOS
• Website: https://www.glaukos.com

Financial Performance

In 2024, Glaukos's revenue was $383.48 million, an increase of 21.85% compared to the previous year's $314.71 million. Losses were -$146.37 million, 8.70% more than in 2023.

Analyst Forecast

According to 13 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price forecast is $161.0, which is an increase of 27.90% from the latest price.

Price Target

$161.0

(27.90% upside)

Analyst Consensus: Strong Buy